Researchers from the University of Sydney, Australia determined that patients with a sedentary lifestyle who engage in routine physical activities lower their risk of nonalcoholic fatty liver disease (NAFLD). The lower risk of problems associated with fatty liver was not contingent upon weight loss, but a direct result from the increased aerobic exercise.

New findings from nutrition researchers at Washington University School of Medicine in St. Louis suggest that it's not whether body fat is stored in the belly that affects metabolic risk factors for diabetes, high blood triglycerides and cardiovascular disease, but whether it collects in the liver.Having too much liver fat is known as nonalcoholic fatty liver disease.

People on low-carbohydrate diets are more dependent on the oxidation of fat in the liver for energy than those on a low-calorie diet, researchers at UT Southwestern Medical Center have found in a small clinical study.

A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease (FLD) lose weight, nor does it improve their liver enzymes or insulin resistance.

It’s easy to go to the gym on a regular basis right after a person buys the gym membership. It’s also easy to skip the gym one day, then the next day and the day after that.

Weekly bouts of moderate aerobic exercise on a bike or treadmill, or a brisk walk, combined with some weightlifting, may cut down levels of fat in the liver by up to 40 percent in people with type 2 diabetes, a study by physical fitness experts at Johns Hopkins shows.

An article recently published in the January 14 issue of the World Journal of Gastroenterology has great significance for NASH. This article will undoubtedly bring about new pathogenesis and treatment of NASH.

While a liver biopsy is the standard method of diagnosis and disease progression for non-alcoholic steatohepatitis (NASH), the most extreme form of nonalcoholic fatty liver disease (NAFLD), researchers previously demonstrated that a less invasive blood test to determine caspase three-generated cytokeratin 18 fragment levels (a noninvasive biomarker test, CK-18) can predict the incidence and magnitude of NASH.